In combination therapy for treating type 2 diabetes (NICE TA315)
NICE TA315 - Canagliflozin in combination therapy for treating type 2 diabetes
MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis
Suitable for initiation in primary care in line with NICE restrictions (see background paragraph)
If a person needs to take 2 antidiabetic drugs, canagliflozin is recommended as a possible treatment for people with type 2 diabetes when taken with a drug called metformin, only if the person:
- cannot take a type of drug called a sulfonylurea or
- is at significant risk of hypoglycaemia or its consequences.
If a person needs to take 3 antidiabetic drugs, canagliflozin is recommended as a possible treatment when taken with either metformin and a sulfonylurea, or metformin and a type of drug called a thiazolidinedione.
Canagliflozin is recommended as a possible treatment taken with insulin, with or without other antidiabetic drugs.
The LSCMMG recommends canagliflozin as the 2nd line ““gliflozin”” (1st line dapagliflozin or empagliflozin).
Reason for decision:
Suitable for initiation in primary care